EXTENDED REPORT

Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density

Corinne Klop,1 Frank de Vries,1,2,3,4 Johannes W J Bijlsma,5 Hubert G M Leufkens,1 Paco M J Welsing5,6

Handling editor Tore K Kvien
1Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
2MRC Lifecourse Epidemiology Unit, Southampton General Hospital, Southampton, UK
3Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands
4Department of Epidemiology, Maastricht University/CAPHRI, Maastricht, The Netherlands
5Department of Rheumatology & Clinical Immunology, University Medical Center, Utrecht, The Netherlands
6Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands

Correspondence to Corinne Klop, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Obbinklaan 100, Utrecht 3571 NJ, The Netherlands; C.Klop@uu.nl

ABSTRACT

Objectives FRAX incorporates rheumatoid arthritis (RA) as a dichotomous predictor for predicting the 10-year risk of hip and major osteoporotic fracture (MOF). However, fracture risk may deviate with disease severity, duration or treatment. Aims were to validate, and if needed to update, UK FRAX for patients with RA and to compare predictive performance with the general population (GP).

Methods Cohort study within UK Clinical Practice Research Datalink (CPRD) (RA: n=11 582, GP: n=38 755), also linked to hospital admissions for hip fracture (CPRD-Hospital Episode Statistics, HES) (RA: n=7221, GP: n=24 227). Predictive performance of UK FRAX without bone mineral density was assessed by discrimination and calibration. Updating methods included recalibration and extension. Differences in predictive performance were assessed by the C-statistic and Net Reclassification Improvement (NRI) using the UK National Osteoporosis Guideline Group intervention thresholds.

Results UK FRAX significantly overestimated fracture risk in patients with RA, both for MOF (mean predicted vs observed 10-year risk: 13.3% vs 8.4%) and hip fracture (CPRD: 5.5% vs 3.1%, CPRD-HES: 5.5% vs 4.1%). Calibration was good for hip fracture in the GP (CPRD-HES: 2.7% vs 2.4%). Discrimination was good for hip fracture (RA: 0.78, GP: 0.83) and moderate for MOF (RA: 0.69, GP: 0.71). Extension of the recalibrated UK FRAX using CPRD-HES with duration of RA disease, glucocorticoids (>7.5 mg/day) and secondary osteoporosis did not improve the NRI (0.01, 95% CI −0.04 to 0.05) or C-statistic (0.78).

Conclusions UK FRAX overestimated fracture risk in RA, but performed well for hip fracture in the GP after linkage to hospitalisations. Extension of the recalibrated UK FRAX did not improve predictive performance.

INTRODUCTION

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterised by destruction of periarticular bone and joint structures and has been associated with osteoporosis.1 2 The risk of hip fracture,3–5 morphometric or clinical spine fracture6 and of other fractures is increased.3 4 The underlying reasons for the increased fracture risk in RA are complex. They may include chronic inflammation, inactivity and an increased risk of falling.1 7 RA has therefore been incorporated as a dichotomous predictor in the WHO FRAX algorithm for predicting the 10-year risk of hip or major osteoporotic fracture (MOF; hip, clinical spine, forearm, humerus).9

There is, however, uncertainty about the predictive performance of FRAX in RA.9 FRAX may underestimate fracture risk in patients with more severe RA, since it does not take the underlying disease activity and resulting joint damage into account. Conflicting results have been reported for correlation of the Health Assessment Questionnaire with clinical fracture risk, which is an often used measure for functional ability in RA10–12 and limited evidence has shown higher fracture risk with longer duration of disease.3 10 On the other hand, FRAX may overestimate fracture risk due to higher mortality among patients with RA as compared with the general population,3 14 since FRAX adjusts fracture risk for competing mortality risk. Furthermore, the role of glucocorticoids on fracture risk in RA is uncertain where fracture risk was found to be independent of glucocorticoid use,15 but preservation of bone mineral density (BMD) has also been described with use of low-dose oral glucocorticoids (GCs).16–18

Therefore, this study aimed to validate UK FRAX for the 10-year risk of hip or MOF in patients with RA and to compare predictive performance with the general population. If needed, methods to recalibrate or extend UK FRAX were applied to improve its predictive performance.

METHODS

Source population
A cohort study was conducted within the Clinical Practice Research Datalink (CPRD) (http://www.cprd.com). This database contains computerised medical records of 625 primary care practices in the UK, representing 8% of the total population. Data recorded in CPRD include demographic information, laboratory tests, primary care diagnoses, specialist referrals, hospital admissions, prescription details and lifestyle variables such as body mass index (BMI), smoking status and alcohol...
consumption. Previous studies have shown high validity of hip fracture registration (>90% was confirmed) and high degrees of accuracy and completeness of data have been shown for other diagnoses and mortality. Linkage of CPRD data to Hospital Episode Statistics (CPRD-HES) was eligible for 62% of the population captured within CPRD, all residing in England. Linkage to HES provides all hospital admissions including the date of discharge and the cause. Approval for this study was given by Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare product Regulatory Agency (MHRA) Database Research (protocol number 15_023A).

**Study population**
Data between 1 January 1987 and 31 December 2013 were extracted from CPRD. HES diagnoses were available between 1 April 1997 and 31 December 2013. We selected all patients with RA at 1 January 2004 (index date), who also had ≥1 year of data collection before the index date. We chose 1 January 2004 as the index date to allow for follow-up of 10 years. RA was defined by a previously validated algorithm\(^2^4\); ≥1 disease-modifying antirheumatic drug (DMARD) prescription after first RA diagnosis code. In line with FRAX, all patients had to be between 40 and 90 years at the index date and were excluded when they were exposed to any antiosteoporosis drug (AOD; bisphosphonates, raloxifene, strontium ranelate, denosumab, parathyroid hormone) ever before the index date.

**Table 1** Characteristics of the RA study population in CPRD and in CPRD-HES

| Characteristic | CPRD (n=11 582) | CPRD-HES (n=7221) |
|---------------|-----------------|-------------------|
| Median follow-up, years (IQR) | 9.0 (4.7–10) | 9.0 (5.3–10) |
| Sex, n (%) | | |
| Male | 3729 (32.2) | 2263 (31.3) |
| Female | 7853 (67.8) | 4958 (68.7) |
| Age, years, mean (±SD) | 62.9 (11.4) | 63.0 (11.5) |
| Body mass index, kg/m\(^2\), mean (±SD) | 26.8 (5.3) | 26.7 (5.3) |
| Missing | 1780 (15.4) | 1086 (15.0) |
| Current smoking, n (%) | 4147 (35.8) | 2573 (35.6) |
| Missing, n (%) | 890 (7.7) | 547 (7.6) |
| Alcohol use ≥3 units per day, n (%) | 580 (5.0) | 371 (5.1) |
| Missing, n (%) | 1759 (15.2) | 1081 (15.0) |
| Previous fracture, n (%) | 1908 (16.5) | 1184 (16.4) |
| Glucocorticoid use yes/no*, n (%) | 1806 (15.6) | 1176 (16.3) |
| Glucocorticoid use, daily dose*, mean (±SD) | 4.9 (3.2) | 4.9 (3.2) |
| 0<GC<2.5 mg/day, n (%) | 508 (4.4) | 295 (4.1) |
| 2.5<GC<7.5 mg/day, n (%) | 1160 (10.0) | 786 (10.9) |
| >7.5 mg/day, n (%) | 305 (2.6) | 200 (2.8) |
| Secondary osteoporosis, n (%) | 580 (5.0) | 372 (5.2) |
| Age of RA onset, years, mean (±SD) | 52.8 (13.5) | 52.8 (13.7) |
| RA disease duration, years, mean (±SD) | 10.1 (9.2) | 10.2 (9.3) |
| <2 years since diagnosis | 1336 (11.5) | 824 (11.4) |
| 2–10 years since diagnosis | 5900 (50.9) | 3671 (50.8) |
| >10 years since diagnosis | 4364 (37.5) | 2726 (37.8) |

*Glucocorticoid use was defined as in FRAX: prescription within 90 days before or ≥2 prescriptions with a mean daily dose of prednisolone (or equivalents) of ≥5 mg in the year before.

We matched up to four controls from the general population to every patient with RA by age, sex and practice in order to directly compare the predictive performance of FRAX between the RA cohort and the general population.

**Outcomes**
The occurrence of hip fracture and the composite of MOF (first of hip, forearm, clinical spine, humerus) were ascertained by medical codes in CPRD. Hip fractures were measured in CPRD-HES by International Classification of Diseases and Related Health problems (ICD)-10 codes S72.0, S72.1 and S72.2.

**Definition of predictors**
In records before the index date, FRAX predictors were determined: age at index date, sex, BMI (most recent), previous fracture at any site (ever before, yes/no), current smoking status (most recent; yes/no), alcohol use (most recent medical code for alcohol abuse or for alcohol use where the daily number of units was ≥3, yes/no), oral glucocorticoid use (prescription within 90 days before or ≥2 prescriptions with a mean daily dose of prednisolone (equivalents) of ≥5 mg in the year before, yes/no), RA (ever before, yes/no) and secondary osteoporosis (ever before, medical code for type 1 diabetes mellitus, osteogenesis imperfecta, hypogonadism, premature menopause, malnutrition or malabsorption or chronic liver disease, yes/no). A parental history of hip fracture was not available. Therefore, we calculated a weighted average of the risks when assuming a parental hip fracture and by assuming absence of parental hip fracture based on a prevalence of parental hip fracture of 12%. An RA-specific predictor, duration of RA disease, was defined as years between the date of RA diagnosis and the index date. Rheumatoid factor-positive RA was not included because of unrealistically low prevalence (1.9%). Finally, oral glucocorticoid use was alternatively defined by mean daily dose in the year before (<2.5, 2.5–7.5 and >7.5 mg/day).

Missing values for BMI, smoking status and alcohol use were imputed by multiple imputation using all predictors and the outcome variable, resulting in five imputed datasets. Analysis by multiple imputation gives unbiased results under the less restrictive missing at random assumption instead of missing completely at random, and generally less bias than complete case analysis if data are missing not at random.

**Statistical analyses**
Predicted 10-year risks of hip fracture and MOF were calculated by UK FRAX (FRAX desktop V3.9) without information on BMD for every patient. This was repeated for each imputed dataset to provide the mean predicted risks (95% CI). The observed 10-year risk of hip fracture and MOF was estimated by the cumulative incidence function (%) to comply with the definition of FRAX, where fracture risk is adjusted for mortality risk (ie, sustaining a fracture within remaining lifetime up to 10 years), and to account for loss to follow-up. Fractures were measured between index date and death, end of the study period (truncated at 10 years following index date, 31 December 2013) or moving out of CPRD, whichever came first. Predictive performance was assessed by means of discrimination (C-statistic) and calibration (on average and by percentiles of predicted risk). In a sensitivity analysis, observed risks among those using AODs after index date were increased inversely proportional to the estimated effect of AODs on hip fracture (assuming a relative risk of 0.5\(^{22}\)) to determine the influence of AOD use on the average observed risk.
Recalibration was performed for hip fracture in CPRD-HES by fitting the log-odds transformed FRAX probabilities (ie, the linear predictor) as a single continuous covariate in a logistic regression model with hospitalisation for hip fracture within 10 years as the outcome variable (CPRD-HES provided full coverage for hip fracture). Thereafter, individual FRAX predictors were added to the linear predictor to determine whether these had an additional predictive effect, and also glucocorticoid dose and duration of RA disease were included. Interactions between the linear predictor and FRAX predictors, glucocorticoid dose and duration of RA disease were also tested. The final (updated) model was derived by including all variables and interactions that were significantly related to hip fracture risk in a multivariable model and then performing backward elimination. In a sensitivity analysis, AOD treatment after the index date and its interaction terms were included into the model.

We determined whether hip fracture prediction was improved for the extended model compared with the recalibrated UK FRAX model in terms of discrimination (C-statistic) and category-based Net Reclassification Improvement (NRI). The NRI incorporates age-specific intervention thresholds set by the National Osteoporosis Guideline Group, which are linked to FRAX output in the UK. Positive NRI values indicate adequate reclassification of risk, whereas negative values indicate inadequate reclassification of risk. Bootstrapping (500 repetitions) was performed to correct the C-statistic for optimism. A shrinkage factor was applied to the β-coefficients of the final models. All statistical analyses were performed using SAS V.9.4 (SAS, Cary, North Carolina, USA). A p value <0.05 was considered statistically significant.

RESULTS
A total of 16 331 patients with RA were identified, of which 1031 were excluded because they were aged <40 or >90 years, and 3718 because they were previously exposed to an AOD. This left 11 582 patients with RA for analyses with 297 and 808 incident cases of hip fracture and MOF and 2733 deaths in CPRD, respectively. HES linkage reduced the number of patients with RA to 7221 (247 hip fractures, 1699 deaths).

Table 1 details the characteristics of the RA population in CPRD and in CPRD-HES. The matched cohort from the general population comprised 38 755 individuals with 536 and 1925 incident cases of hip fracture and MOF, and 5636 deaths in CPRD, respectively. HES linkage reduced the number to 24 227 (476 hip fractures, 3550 deaths).

UK FRAX overestimated fracture risk among the RA population in CPRD, both for MOF (mean predicted vs observed 10-year risk: 13.3% vs 8.4%, 95% CI 7.8 to 9.0) and for hip fracture (5.5% vs 3.1%, 95% CI 2.8 to 3.5) (figure 1). Linkage to hospitalisation data for hip fracture attenuated the overestimation, but it remained significant (5.5% vs 4.1%, 95% CI 3.6 to 4.6) (figure 2A). The AOD-adjusted mean observed risk was 4.6% (25% received an AOD). C-statistics were 0.78 and 0.69 for hip fracture and MOF, respectively.

In the general population, UK FRAX also overestimated the risk of MOF (8.6% vs 6.2%, 95% CI 5.9 to 6.4) and hip fracture in CPRD (2.7% vs 1.8%, 95% CI 1.6 to 1.9). After linkage to hospitalisations, there was close agreement between predicted and observed risks of hip fracture (2.7% vs 2.4%, 95% CI 2.2 to 2.7) (figure 2B). The AOD-adjusted mean observed risk was 2.5% (6% received an AOD). C-statistics were 0.83 and 0.71 for hip fracture and MOF, respectively.

The higher observed risk of hip fracture in CPRD-HES as compared with CPRD indicates underascertainment of hip fractures in CPRD. Updating of UK FRAX was therefore not performed for MOF but only for hip fracture in CPRD-HES for patients with RA. The recalibrated UK FRAX model for hip fracture in RA is shown in table 2. The extended model included the linear predictor, duration of RA disease and its interaction with the linear predictor, high-dose glucocorticoids (>7.5 mg/day) and secondary osteoporosis (table 2). In
sensitivity analyses, AOD treatment and its interaction with the linear predictor were dropped from the recalibrated model (adjusted (adj.) OR for AOD treatment: 0.6, 95% CI 0.3 to 1.1, adj. OR for interaction: 0.8, 95% CI 0.7 to 1.1) and the extended model (adj. ORs of 0.6, 95% CI 0.3 to 1.1 and 0.8, 95% CI 0.7 to 1.1), respectively, during backward elimination.

Calibration of the extended model was good (intercept: 0.00, β-linear predictor: 1.02) (figure 3). The C-statistic was 0.78. Extension did not improve correct classification of hip fracture cases and non-cases when compared with the recalibrated UK FRAX model with an NRI of 0.01 (95% CI −0.04 to 0.05) (table 3).

**DISCUSSION**

UK FRAX overestimated the risk of hip fracture and MOF in CPRD for both the RA population and the general population. Linkage to hip fracture hospitalisations changed this finding, where calibration was good for the general population but overestimation of UK FRAX for hip fracture remained among patients with RA. Discrimination was good for hip fracture and moderate for MOF in both populations. Extension of the recalibrated UK FRAX model for RA with duration of RA disease, high-dose glucocorticoids, and secondary osteoporosis did not improve predictive performance.

Little is known about fracture risk assessment in RA and we are not aware of studies that have determined discrimination and calibration of FRAX, which has been developed and validated in the general population, in this subpopulation. Lee et al. applied the Korean FRAX algorithm to 545 Korean patients with RA, and found no difference in fracture incidence between those who met the FRAX thresholds for treatment and those who had osteoporosis. However, the Korean FRAX model was not validated, which limits the interpretation of results.

In order to determine whether external influences other than RA itself influenced the performance of FRAX, we have also evaluated FRAX in a random sample from the general population. Worldwide, a limited number of independent external validation studies have been performed for FRAX and even fewer have assessed calibration. To date, one study has evaluated calibration of FRAX in the general population of the UK. This study was performed in the QResearch primary care database, where UK FRAX overestimated hip fracture risk in each percentile of predicted risk. This finding was likely the result of underascertainment of (hip) fractures in primary care data. Indeed, we found calibration to be improved upon linkage of CPRD to HES data. It remains, however, unclear how well UK FRAX calibrates for MOF risk. The higher discrimination of FRAX for hip fracture as compared with MOF is well in line with findings from other external validation studies. This may be the result of a different association of risk factors for different fracture types.

A possible explanation for the overestimation of hip fracture risk by FRAX in RA is higher competing mortality as compared with the general population. Their lifespan is reduced by 3–10 years, for which no improvement has been found over the past decades. Also, all patients with RA were exposed to DMARDs. These drugs have been associated with a protective effect on loss of BMD and reduced fracture risk, but evidence has been conflicting. Biologics are now frequently used among patients with RA and may further reduce fracture risk, although the adjusted risk of non-vertebral fracture has been reported to be similar across patients with RA starting a tumour necrosis factor-α inhibitor, methotrexate or other non-biologic DMARDs. In addition, AOD treatment may have influenced observed fracture risks, but our results suggest that the overestimation of FRAX was largely independent of AOD treatment status. The adjusted observed risk for hip fracture remained
lower than predicted when we assumed a 50% relative risk reduction among all patients treated with AOD. Similarly, a Canadian prospective cohort study found that AOD treatment status did not appear to interfere with the predictive performance of the Canadian FRAX algorithm in the general population. Treatment duration influenced this finding for hip fracture but not for MOF, where observed risks were significantly lower than predicted among patients adhering to AOD treatment for at least 5 years. The insufficient adherence to AOD treatment in clinical practice is well known, which has been shown to blunt the antifracture effectiveness, and may explain the independence of FRAX calibration from AOD treatment status.

The finding that overestimation of UK FRAX for risk of hip fracture increased with longer duration of RA may relate to increased competing mortality with longer duration of RA disease, and greater loss of BMD during recent onset of disease. Second, patients with RA, who were exposed to high-dose glucocorticoids, had a lower risk of hip fracture, which was independent from the risk of hip fracture with use of glucocorticoids as defined in FRAX. The role of glucocorticoids on fracture risk in RA is not well understood. Inconsistent results were reported for the association between bone loss and exposure to low-dose to medium-dose glucocorticoids. Our finding may be related to increased mortality among those who are treated with high-dose GCs. The present study, however, was not designed to determine the causal association between glucocorticoid dose and hip fracture risk in RA. And third, secondary osteoporosis was selected as a predictor for the 10-year risk of hip fracture on top of FRAX. FRAX neglects the influence of secondary osteoporosis when RA is present, but our finding is not in line with this assumption. Most importantly, however, is that our results show that their addition to the recalibrated UK FRAX did not improve identification of RA individuals at high risk of hip fracture.

This study has several strengths. The included patients with RA were representative for the general RA population with a similar age at onset of RA disease and gender distribution as was previously reported. In addition, this is the first study that provides results for calibration of UK FRAX for RA and also for the general population, where hip fractures were completely captured and which enabled 10 years of follow-up. A limitation was that we had no data on BMD and RA disease severity parameters besides duration of RA disease. When access to dual-energy x-ray absorptiometry (DXA) is limited, however, FRAX without BMD may be used instead and a strong correlation between fracture risks by FRAX with and without BMD has been shown. Furthermore, information on parental hip fracture was not available. Therefore, we have calculated weighted average risks by assuming the prevalence of parental hip fracture as was observed in the FRAX developmental cohorts. This was done not to influence the average calibration and to evaluate methods to improve this, and this method resulted in good calibration of FRAX for hip fracture in the general population. We were also not able to determine whether duration of RA disease interacted with the individual predictors since β-coefficients of the original FRAX algorithm are not publicly available.

In conclusion, UK FRAX overestimated hip fracture and MOF risk in both populations. Updating of UK FRAX for RA beyond recalibration did not improve predictive performance for hip fracture.

**Acknowledgements** We wish to acknowledge Ms Thomas for providing the RA diagnostic medical code lists, which were used for validation of RA diagnosis in the former version of Clinical Practice Research Datalink (general practice research database; GPRD).

**Contributors** Conceived and designed the experiments: CK, FdV, JWJB, HGML and PMIW. Analysed the data: CK and PMIW. Wrote the paper: CK. Reviewed the manuscript: CK, FdV, JWJB, HGML and PMIW.

**Funding** This study was supported by a research grant from the Netherlands Organization for Health Research and Development (ZonMW; grant number 113101007).

**Competing interests** The Division of Pharmacoeconomics and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, employing authors CK and FdV, has received unrestricted funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (ZIN), the Royal Dutch Pharmacists Association (KNMP), the private-public funded Top Institute Pharma (http://www.tiphera.nl), includes cofunding from universities, government and industry, the EU Innovative Medicines Initiative (IMI), the EU 7th Framework Program (FP7), the Dutch Ministry of Health and industry (including GlaxoSmithKline, Pfizer and others); HGML is a researcher at The WHO Collaborating Centre for Pharmaceutical Policy and Regulation, which receives no direct funding or donations from private parties, including pharma industry. Research funding from public–private partnerships, for example, IMI, TI Pharma (http://www.tiphera.nl) is accepted under the condition that no company-specific product or company-related study is conducted. The Centre has received unrestricted research funding from public sources, for example, the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the EU 7th Framework Program (FP7), the Dutch Medicines Evaluation Board (MEB) and the Dutch Ministry of Health.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**REFERENCES**

1. Kaz H, Johnson D, Kerry S, et al. Fall-related risk factors and osteoporosis in women with rheumatoid arthritis. *Rheumatology (Oxford)* 2004;43:1267–71.

2. Ørstavik RE, Haugeberg G, Mowinckel P, et al. Vertebral deformities in rheumatoid arthritis. A comparison with population-based controls. *Arch Intern Med* 2004;164:420–5.

3. van Staa TP, Guermazi A, Cooper C, et al. The use of clinical risk factors enhances the prediction of hip and osteoporotic fractures in older adults. *Ann Rheum Dis* 2009;68:1799–804.

4. Klibi C, Macfarlane GJ, Zhang Y, et al. Clinical risk factors and measures of fracture risk in women with rheumatoid arthritis. *Arthritis Care Res* 2012;64:1561–72.

5. Felsenberg D, Auto M, Song X, et al. The role of glucocorticoids on influencing fracture risk, T score, and BMD in patients with rheumatoid arthritis. *J Rheumatol* 2006;33:1000–10.

6. Zhou J, Zhang L, Song X, et al. The effect of glucocorticoids on the risk of hip fractures in patients with rheumatoid arthritis. *Calcif Tissue Int* 2012;90:126–33.

7. Klibi C, Auto M, Song X, et al. The role of glucocorticoids on influencing fracture risk, T score, and BMD in patients with rheumatoid arthritis. *J Rheumatol* 2006;33:1000–10.

8. Klibi C, Auto M, Song X, et al. The role of glucocorticoids on influencing fracture risk, T score, and BMD in patients with rheumatoid arthritis. *J Rheumatol* 2006;33:1000–10.

9. Zhou J, Zhang L, Song X, et al. The effect of glucocorticoids on the risk of hip fractures in patients with rheumatoid arthritis. *Calcif Tissue Int* 2012;90:126–33.

10. Klibi C, Auto M, Song X, et al. The role of glucocorticoids on influencing fracture risk, T score, and BMD in patients with rheumatoid arthritis. *J Rheumatol* 2006;33:1000–10.

11. Klibi C, Auto M, Song X, et al. The role of glucocorticoids on influencing fracture risk, T score, and BMD in patients with rheumatoid arthritis. *J Rheumatol* 2006;33:1000–10.

12. Klibi C, Auto M, Song X, et al. The role of glucocorticoids on influencing fracture risk, T score, and BMD in patients with rheumatoid arthritis. *J Rheumatol* 2006;33:1000–10.
Clinical and epidemiological research

13 El Maghraoui A, Rezgi A, Mounach A, et al. Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment. *Rheumatology (Oxford)* 2010;49:1303–10.

14 Myasoedova E, Davis JM III, Crowson CS, et al. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. *Curr Rheumatol Rep* 2010;12:379–85.

15 Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. *Ann Rheum Dis* 2004;63:797–803.

16 Boers M, Verheozen AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in active rheumatoid arthritis. *Lancet* 1997;350:309–18.

17 Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisolone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. *Ann Intern Med* 1993;119:963–8.

18 Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. *Arthritis Rheum* 2005;52:3360–70.

19 Van Staa TP, Abenhaim L, Cooper C, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *Br J Gen Pract* 2008;58:679–86.

20 Herrett E, Thomas SL, Schorren WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *Br J Clin Pharmacol* 2010;69:4–14.

21 Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. *Br J Gen Pract* 2010;60:e128–36.

22 Lewis JD, Brixeniger C. Agreement between GPDR smoking data: a survey of general practitioners and a population-based survey. *Pharmacoepidemiol Drug Saf* 2004;13:437–41.

23 Dregan A, Moller H, Murray-Thomas T, et al. Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study. *Cancer Epidemiol* 2012;36:425–9.

24 Thomas SL, Edwards CJ, Smeeth L, et al. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? *Arthritis Rheum* 2008;59:1314–21.

25 Leslie WD, Lix LM, Wu X, et al. Competing mortality and fracture risk assessment. *Osteoporos Int* 2013;24:681–8.

26 Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. *J Clin Endocrinol Metab* 2012;97:1871–80.

27 Janssen KM, Moons KGM, Kalkman CJ, et al. Updating methods improved the performance of a clinical prediction model in new patients. *J Clin Epidemiol* 2008;61:76–86.

28 Steyerberg EW. Clinical prediction models: A practical approach to development, validation, and updating. Springer. 2009.

29 Leening MJ, Vedder MM, Witteman JC, et al. Net Reclassification Improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. *Ann Intern Med* 2014;160:122–31.

30 Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. *Ann Intern Med* 2009;150:795–802.

31 Brigham & Women’s Hospital. Division of Preventative Medicine. Risk prediction modeling. SAS Macro’s. http://ncook.bwh.harvard.edu/sas-macros.html (accessed 26 Sept 2015).

32 Furuya T, Hosoi T, Saito S, et al. Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis. *Clin Rheumatol* 2011;30:1105–11.

33 Lee JH, Suh YS, Koh JH, et al. The risk of osteoporotic fractures according to the FRAX model in Korean patients with rheumatoid arthritis. *J Korean Med Sci* 2014;29:1082–9.

34 Marques A, Ferreira RJ, Santos E, et al. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. *Ann Rheum Dis* 2015;74:1958–67.

35 Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. *BMJ* 2009;339:b4229.

36 Radovits BJ, Fransen J, Al Shamma S, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2010;62:362–70.

37 Kim SY, Schneeweiss S, Liu J, et al. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. *J Bone Miner Res* 2012;27:789–96.

38 Leslie WD, Lix LM, Johansson H, et al. Manitoba Bone Density Program. Does osteoporosis therapy invalidate FRAX for fracture prediction? *J Bone Miner Res* 2012;27:1243–51.

39 Ross S, Samuels E, Gairky K, et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. *Value Health* 2011;14:571–81.

40 van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Excess mortality in rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database. A two-year randomized trial. *Arthritis Rheum* 2005;52:3360–70.

41 Del Rincón I, Battafarano DR, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. *Arthritis Rheumatol* 2016;68:264–72.

42 Schols AM, Wesseling G, Kester AD, et al. Does recent increased mortality risk in COPD patients treated with oral glucocorticoids. *Eur Respir J* 2001;17:337–42.

43 Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. *JAMA* 2011;305:2525–31.

44 Crane JM, Juneja M, Allen J, et al. Epidemiology and treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population. *Arthritis Care Res (Hoboken)* 2015;67:1646–55.

45 Kanis JA, Johrell D. Requirements for DXA for the management of osteoporosis in Europe. *Osteoporos Int* 2005;16:229–38.

46 Curtis JR, Lastor A, Becker DJ, et al. The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. *Osteoporos Int* 2009;20:1553–61.

47 Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. *Osteoporos Int* 2012;23:75–85.